Validation of a rapid, non-radioactive method to quantify internalisation of G-protein coupled receptors

Maikel Jongsma · Urszula M. Florczyk · Mariëlle C. Hendriks-Balk · Martin C. Michel · Stephan L. M. Peters · Astrid E. Alewijnse

Abstract Agonist exposure can cause internalisation of G-protein coupled receptors (GPCRs), which may be a part of desensitisation but also of cellular signalling. Previous methods to study internalisation have been tedious or only poorly quantitative. Therefore, we have developed and validated a quantitative method using a sphingosine-1-phosphate (S1P) receptor as a model. Because of a lack of suitable binding studies, it has been difficult to study S1P receptor internalisation. Using a N-terminal HisG-tag, S1P1 receptors on the cell membrane can be visualised via immunocytochemistry with a specific anti-HisG antibody. S1P-induced internalisation was concentration dependent and was quantified using a microplate reader, detecting either absorbance, a fluorescent or luminescent signal, depending on the antibodies used. Among those, the fluorescence detection method was the most convenient to use. The relative ease of this method makes it suitable to measure a large number of data points, e.g. to compare the potency and efficacy of receptor ligands.

Keywords Sphingosine-1-phosphate receptors · HisG-tag · Quantification · Internalisation · Cellular trafficking · G-protein coupled receptor

Introduction

When chronically exposed to an agonist, G-protein coupled receptors (GPCRs) can undergo desensitisation, i.e. the response to a given level of agonist exposure declines, and/or more agonist is required to maintain the same response. Various mechanisms can be involved in desensitisation, some of which directly affect receptor responsiveness. One of these mechanisms involves phosphorylation of activated receptors by GPCR kinases (GRKs). This enables binding of arrestins to the receptor, leading to uncoupling from the G-protein and hence impaired signalling. Another, not necessarily mutually exclusive mechanism of desensitisation is internalisation of the receptor, which can be either homologous (because of activation of the receptor) or heterologous (because of activation of other receptors or to other stimuli). Receptor internalisation can be arrestin-dependent or independent (Bünemann and Hosey 1999) and involves translocation of the receptor from the cell membrane to the inside of the cell. There, it is entrapped inside clathrin-coated pits and can undergo either degradation or resensitisation. Several approaches have been used in the past to detect and quantify GPCR internalisation. One classical method involves homogenisation of tissues or cells, differential centrifugation to yield a plasma membrane and a microsomal fraction followed by electrophoresis and autoradiographical analyses of the receptor of interest in both fractions (Simpson et al. 1984). Another classical method involves labeling of all receptors in intact cells with a lipophilic radioligand and competition by a hydrophilic ligand, which will replace the radioligand from sites at the cell surface but not from those entrapped intracellularly (Staehelin et al. 1983). More recently, genetic approaches have been used. An example is the use of a C-terminal green fluorescent protein (GFP; Barak et al. 1997; Kallal et al. 1998) to monitor receptor localisation after ligand stimulation sometimes combined with an algorithm to discriminate between internalised and membrane-bound receptors (Conway et al. 1999; Fukunaga et al. 2006; Schlag et al. 2004; Hirasaki et al. 2005). This
latter method uses a cell-based fluorescence imaging system
ArrayScanII, where the amount of internalised receptor/GFP
spots are counted and normalised against the number of
nuclei stained with Hoechst 33342. However, a GFP, or other
fluorescent tag, is relatively large (200–300 amino acids) and
can influence receptor function (McLean and Milligan
2000). Other methods use a combination of techniques, like
quantitative flow cytometry analysis of the cell surface
receptors and immunocytochemical confocal microscopy
analysis to visualise the sub-cellular localisation of the
receptor of interest (Hirasawa et al. 1998).

Detailed quantitative studies of internalisation are of
interest as this process can be the mechanism of underlying
physiological and pharmacological effects. For example,
receptor internalisation is thought to underlie the modula-
tion of immune function by sphingosine-1-phosphate (S1P;
Matloubian et al. 2004). This also appears to be the
mechanism of action of the immunosuppressive drug
FTY720 ( fingolimod; Chiba et al. 2006; LaMontagne et
al. 2006), which is undergoing clinical trials for the

treatment of multiple sclerosis and previously also for renal
graft rejection (Budde et al. 2002; Kappos et al. 2006).

In our search to quantify internalisation of membrane
receptors in a fast and easy way, we have setup a method,
which uses an N-terminal HisG (6xHis+Gly)-tagged S1P1
receptor. Because the HisG-tag is N-terminal, it is extra-
cellular. Therefore, when immunocytochemistry is per-
formed without permeabilisation, only membrane-bound,
tagged receptors will be detected. This way, internalisation
is quantified as a difference in membrane-fluorescence
between unstimulated and agonist-stimulated cells.

The use of small, N-terminal tags has been described
before (Daunt et al. 1997; Vicentic et al. 2002; Wozniak and
Limbird 1996; Von Zastrow et al. 1993; Miller 2004). Of
these, Daunt et al. 1997 described a method where cells were
plated onto 24 well tissue culture dishes. After stimulations
with an agonist, incubations with first and second antibodies
followed. Measurements were done after adding alkaline
phosphatase substrate, resulting in a colorimetric reading. In
this paper, we now describe the validation of a similar
method by testing various antibody combinations and
detection methods to quantify internalisation of N-terminal
HisG-tagged receptors. This resulted in immunocytochemi-
cal method using a specific anti-HisG first antibody
combined with a fluorescent second antibody (AlexaFluor®
488) as our preferred choice. The signal can either be
visualised under the fluorescence microscope or measured in
a fluorescence microplate reader. The latter results in
quantitative measurement of the decrease in signal caused
by receptor internalisation, in a direct, sensitive and fast way.

Materials and methods

Materials

pcDNA3.1 containing the entire coding region of the
human S1P1 receptor was purchased from UMR cDNA
Resource Center (Rolla, MO).
Cell culture media, hygromycine B, Lipofectamine™2000, pcDNA3.1/His C, pOG44, CHO-FlpIn cells, Alexa Fluor® 488 goat anti-mouse (IgG), anti-HisG (mouse monoclonal IgG2a), anti-HisG-horse radish peroxidase (HRP; mouse monoclonal IgG2a), pcDNA5/FRT/TO, NuPAGE® System, NuPAGE® Novex 4–12% Bis-Tris gel, MES running buffer, NuPAGE® transfer buffer and Invitrolon™ PVDF blotting membranes were obtained from Invitrogen (Breda, The Netherlands). BCA™ Protein Assay Kit was obtained from Pierce (Etten-Leur, The Netherlands). Formaldehyde solution was obtained from Sigma (Zwijndrecht, The Netherlands). Restriction enzymes (BamHI, XhoI, EcoRI and HindIII) were obtained from Fermentas Life Sciences (St. Leon-Rot, Germany). Black, clear bottom 96 well plates were obtained from Greiner Bio One (Alphen aan den Rijn, The Netherlands). S1P was obtained from Avanti-Polar Lipids (via Instruchemie B.V., Delfzijl, The Netherlands). Chamber slides were obtained from Nunc (Amsterdam, The Netherlands). BM Chemiluminescence Blotting Substrate [POD] and ABTS [2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)] were obtained from Roche (Mannheim, Germany). Hyperfilm ECL was obtained from Amersham Biosciences (Diegem, Belgium). SEW2871 (5-(4-Phenyl-5-trifluoromethylthiophen-2-yl)-3-(3-trifluoromethylphenyl)-1,2,4-oxadiazole) was obtained from Calbiochem (via VWR, Amsterdam, The Netherlands). Goat anti-mouse-HRP was obtained from Jackson ImmunoResearch Europe (via Sanbio B.V., Uden, The Netherlands). RIPA buffer was obtained from Boston Bio Products (Worcester, UK). Halt protease inhibitor cocktail was obtained from Pierce (via Perbio Science Nederland B.V. Etten-Leur, The Netherlands).

**Fig. 3** Fluorescence microscope pictures of CHO-FlpIn cells stably expressing the HisG-S1P₁ using a mouse anti-HisG first antibody and AlexaFluor® 488 goat anti-mouse second antibody. Cells were stimulated for 30 min with 1 μM S1P or 10 μM SEW2871 at either 37°C (left panel) or 4°C (right panel). Images shown are from one typical experiment out of four.
Molecular cloning and transfection

An N-terminal HisG-tag was added to the S1P1 receptor via cloning into pcDNA3.1/HisC using BamHI and XhoI. A second cloning step was done using HindIII and XhoI to clone the HisG-tagged S1P1 receptor into the expression vector pcDNA5/FRT/TO. Transfection of plasmids into CHO-FlpIn cells and cell culture was done as described previously (Jongsma et al. 2006).

Western blot

Cells were washed and scraped in PBS, spun down and lysed in RIPA buffer with protease inhibitor. Protein concentration was determined using the BCA kit according to the manufacturer’s protocol. Ten micrograms of protein were loaded onto a 4–12% NuPAGE® Bis–Tris Gel. Electrophoresis was carried out at 200 V for 40 min in NuPAGE® MES running buffer. Protein was transferred to Invitrolon™ PVDF blotting membranes at 30 V for 1 h. The membrane was blocked for 1 h at room temperature in 50 mg/ml non-fat dry milk in PBS followed by overnight incubation at 4°C with a dilution of 1:5,000 for mouse anti-HisG. After washing with PBS-Tween (0.1%), the membrane was incubated with a 1:20,000 dilution of goat anti-mouse-HRP IgG at room temperature. Detection was done using BM Chemiluminescence Blotting Substrate and Hyperfilm ECL.

Immunocytochemistry

Cells (40,000 cells/well) were plated on day 1 in 96 wells black, clear bottom plates or eight well chamber slides. The

![Fluorescence microscope pictures of CHO-FlpIn cells stably expressing the HisG-S1P1 receptor using a mouse anti-HisG first antibody and AlexaFluor® 488 goat anti-mouse second antibody. Cells were stimulated with S1P at the indicated concentrations at 37°C for 30 min. Images shown are from one typical experiment out of four experiments.](image-url)
next day, the medium was changed to serum-free medium. After incubation overnight, cells were stimulated with the indicated ligand in serum-free medium for 30 min at 37°C, unless otherwise indicated. The stimulation solutions were removed, and cells were fixed by applying 4% v/v formaldehyde in PBS for 15 min at room temperature. After washing three times with PBS, cells were incubated with the first antibody for 1 h at room temperature. Cells were washed again three times with PBS and, if necessary, incubated with the second antibody for 1 h at room temperature. Cells were washed three times with PBS followed by measurements on a Victor2 (Wallac, Perkin Elmer). The following antibody combinations were used: mouse anti-HisG 1:200 with AlexaFluor® 488 goat anti-mouse 1:500, mouse anti-HisG-HRP 1:200 and mouse anti-HisG 1:200 with goat anti-mouse-HRP 1:500. In case an HRP-bound antibody was used, either ABTS solution (50 μg/ml) or BM Chemiluminescence Blotting Substrate was added to generate an absorbance or luminescence signal, respectively. For the absorbance signal, a 405-nm filter was used; for the fluorescent signal, a 490-nm excitation and a 535-nm emission filter were used.

Data analysis

Concentration response curves were analysed by fitting sigmoidal functions to the experimental data using Prism 4 (Graphpad Software, San Diego, CA). Data are expressed as means±SEM. Differences between groups were compared using a one way analysis of variance with a Dunnett’s correction or a Student’s t test where appropriate. P<0.05 was considered significant.

Results

Characterisation of the HisG-tagged S1P1 receptor

The presence of HisG-S1P1 receptor in stably transfected CHO-FlpIn cells was confirmed in Western blot analysis as a band of approximately 50 kDa (Fig. 1). The HisG-S1P1 receptor was also visualised in the cell membrane by fluorescence microscopy using AlexaFluor® 488 goat anti-mouse as a secondary antibody (Fig. 2). CHO-FlpIn cells stably expressing the untagged S1P1 receptor were used as a negative control for both detection methods (Figs. 1 and 2). Addition of the N-terminal HisG-tag to the S1P1 receptor did not influence signaling via this receptor as it did not significantly alter the potency of S1P to inhibit forskolin-stimulated cAMP accumulation (pEC50 S1P1 9.0±0.1 vs HisG-S1P1 8.9±0.1; n=6), measured as described previously (Jongsma et al. 2006).

Internalisation of the S1P1 receptor

A 30-min incubation with 1 μM of S1P or 10 μM of the selective S1P1 agonist SEW2871 (Sanna et al. 2004) at 37°C decreased fluorescence (Fig. 3a, c, e). No such decrease in fluorescence was seen when cells were incubated with either agonist at 4°C (Fig. 3b, d, f). S1P concentration dependently internalised the HisG-S1P1 receptor as visualised with a fluorescence microscope (Fig. 4). Such decrease in fluorescence was also measured using a fluorescence microplate reader. The fluorescent signal of cells stably expressing the HisG-S1P1 receptor was significantly higher than for cells stably expressing the untagged S1P1 receptor. Stimulation with S1P (1 μM) for 30 min significantly decreased this signal (Fig. 5).

Choice of detection method

Instead of the antibody combination mouse anti-HisG and AlexaFluor® 488 goat anti-mouse (Fig. 6a), other combinations were tested to optimise the method. The use of a first antibody mouse anti-HisG-HRP (Fig. 6b) or a first antibody mouse anti-HisG with a second antibody goat anti-mouse-HRP (Fig. 6c) combined with the BM Chemiluminescence Blotting Substrate (POD) resulted in a luminescence signal, which proved to be very sensitive. However, the signal was very unstable over time, which required the addition of the substrate by the microplate reader. The combination of a first antibody mouse anti-
HisG-HRP (Fig. 6d) or a first antibody mouse anti-HisG with a second antibody goat anti-mouse-HRP (Fig. 6e) combined with ABTS resulted in an absorbance signal. This signal however, had less sensitivity compared to the other two detection methods. The use of a first antibody mouse anti-HisG-HRP resulted in a loss of sensitivity compared to the combination of a first antibody mouse anti-HisG with a second antibody goat anti-mouse-HRP. When the combination of a first antibody mouse anti-HisG and a second antibody AlexaFluor® 488 goat anti-mouse was used, we measured a concentration-dependent internalisation of HisG-S1P₁ after stimulation with either S1P or SEW2871 (pEC₅₀ S1P=7.4±0.1 [n=8] and pEC₅₀ SEW2871=5.7±0.2 [n=3], respectively; Fig. 7).

**Discussion**

Previously reported methods to study the internalisation of GPCRs were very labor intensive, required specific equipment, added bulky tags and/or were poorly quantitative. We have developed and validated a method that uses stably transfected cells expressing a receptor with a minor modification only, i.e. an N-terminal HisG-tag, which did not influence receptor signaling. Several
antibody combinations and detection methods were tested. The luminescent approach was very sensitive but highly dependent on strict adherence to a specific time interval between substrate addition and actual signal measurement. The absorbent signal obtained using another detection substrate resulted in a loss of sensitivity. The antibody combination of a first HisG specific antibody and a second AlexaFluor® 488 fluorescent antibody proved the most convenient, resulting in a sensitive and stable signal. Compared to previously published methods using a similar approach (Daunt et al. 1997; Vicentic et al. 2002; Wozniak and Limbird 1996; Von Zastrow et al. 1993), this immunocytochemical detection of the N-terminal HisG-tag is suitable to assess a large number of samples, e.g. to construct detailed concentration response curves and/or compare multiple ligands. In this regard, we showed that S1P was approximately 50 times more potent than SEW2871 in internalising the HisG-S1P receptor. This is in good agreement with the previously reported potency difference between the two agonists for activating the receptor (Sanna et al. 2004). As comparable methods have been described for adrenergic receptors as mentioned above (Daunt et al. 1997; Vicentic et al. 2002; Wozniak and Limbird 1996; Von Zastrow et al. 1993), it is likely that the method we described here is also suitable for receptors other than our model receptor, S1P.

While our technique does not allow following internalisation in real time, the ability to process a large number of samples compensates for that by studying multiple time points. The only limitation to our method is the inability to measure internalisation of endogenous receptors. However, this would be possible when specific receptor antibodies are available, which is not yet the case for our model receptor.

In conclusion, we have validated a method to quantitatively measure receptor internalisation in which we use an N-terminal HisG-tag combined with immunocytochemistry. It proves to be sensitive enough to discriminate between different receptor ligands in a fast and non-radioactive way.

References

Barak LS, Ferguson SSG, Zhang J, Martenson C, Meyer T, Caron MG (1997) Internal trafficking and surface mobility of a functionally intact β2-adrenergic receptor-green fluorescent protein conjugate. Mol Pharmacol 51:177–184

Budde K, Schmouder RL, Brunkhorst R, Nashan B, Lucker PW, Mayer T, Choudhury S, Skerjanec A, Kraus G, Neumayer HH (2002) First human trial of FTY720, a novel immunomodulator, in stable renal transplant patients. J Am Soc Nephrol 13:1073–1083

Bünemann M, Hosey MM (1999) G-protein coupled receptor kinases as modulators of G-protein signaling. J Physiol 517:5–23

Chiba K, Matsuyuki H, Maeda Y, Sugahara K (2006) Role of sphingosine 1-phosphate receptor type 1 in lymphocyte egress from secondary lymphoid tissues and thymus. Cell Mol Immunol 3:11–19

Conway BR, Minor LK, Xu JZ, Gunnet JW, DeBiasio R, D’Andrea MR, Rubin R, DeBiasio R, Giuliano K, DeBiasio L, Demarest KT (1999) Quantification of G-protein coupled receptor internalisation using G-protein coupled receptor–green fluorescent protein conjugates with the ArrayScan trade mark high-content screening system. J Biomol Screen 4:75–86

Daunt DA, Hurt C, Hein L, Kallio J, Feng F, Kobilka BK (1997) Subtype-specific intracellular trafficking of α2-adrenergic receptors. Mol Pharmacol 51:711–720

Fukunaga S, Setoguchi S, Hirasawa A, Tsujimoto G (2006) Monitoring ligand-mediated internalization of G protein-coupled receptor as a novel pharmacological approach. Life Sci 80:17–23

Hirasawa A, Awaji T, Sugawara T, Tsujimoto A, Tsujimoto G (1998) Differential mechanism for the cell surface sorting and agonist-promoted internalisation of the α1B-adrenoceptor. Br J Pharmacol 124:55–62

Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G (2005) Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11:90–94

Jongsma M, Hendriks-Balk MC, Michel MC, Peters SLM, Alewijswie AE (2006) BML-241 fails to display selective antagonism at the sphingosine-1-phosphate receptor, S1P1. Br J Pharmacol 149:277–282

Kallal L, Gagnon AW, Penn RB, Benovic JL (1998) Visualization of agonist-induced sequestration and down-regulation of a green fluorescent protein-tagged β2-adrenergic receptor. J Biol Chem 273:322–328

Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW (2006) Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 355:1124–1140

LaMontagne K, Littlewood-Evans A, Schnell C, O’Reilly T, Wyder L, Sanchez T, Probst B, Butler J, Wood A, Liu G, Billy E, Theuer A, Hla T, Wood J (2006) Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res 66:221–231

Matlioubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG (2004) Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1, Nature 427:355–360

McLean AJ, Milligan G (2000) Ligand regulation of green fluorescent protein-tagged β2-adrenergic receptor. J Biol Chem 275:3228–3238

Miller JW (2004) Tracking G protein-coupled receptor trafficking using Odyssey imaging. Published August by LI-COR Biosciences (http://www.licor.com/bio/PDF/Miller_GPCR.pdf accession date Jan 12 2007)

Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, Webb B, Lefebvre S, Chun J, Gray N, Rosen H (2004) Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P5, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem 279:13839–13848

Schlag BD, Lou Z, Fennell M, Dunlop J (2004) Ligand dependency of 5-hydroxytryptamine 2C receptor internalization. J Pharmacol Exp Ther 310:865–870

Simpson IA, Hedo JA, Cushman SW (1984) Insulin-induced internalisation of the insulin receptor in the isolated rat adipose cell. Diabetes 33:13–18
Stachelin M, Simons P, Jaeggi K, Wigger N (1983) CGP-12177: a hydrophilic beta-adrenergic receptor radioligand reveals high affinity binding of agonists to intact cells. J Biol Chem 258:3496–3502

Vicentic A, Robeva A, Rogge G, Uberti M, Minneman KP (2002) Biochemistry and pharmacology of epitope-tagged α1-adrenergic receptor subtypes. J Pharmacol Exp Ther 302:58–65

Wozniak M, Limbird LE (1996) The three α2-adrenergic receptor subtypes achieve basolateral localization in Madin-Darby canina kidney II cells via different targeting mechanisms. J Biol Chem 271:5017–5024

Von Zastrow M, Link R, Daunt D, Barsch G, Kobilka B (1993) Subtype-specific differences in the intracellular sorting of G protein-coupled receptors. J Biol Chem 268:763–766